Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Renata Hejnova"'
Autor:
Radoslav Danis PharmDr, Michal Mego MD, DSc, Mariya Antonova Mgr, Radka Stepanova Mgr, Adam Svobodnik PhD, Renata Hejnova Mgr, Martin Wawruch MD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 21 (2022)
Background: Chemoradiotherapy-induced gastrointestinal toxicity may lead to a significant impairment of the oncological patient’s quality of life, as well as to reduced adherence to the treatment, which may have a negative impact on survival and mo
Externí odkaz:
https://doaj.org/article/c654f202900a4b9eb7bd031826c2f028
Autor:
Radka Obermannova, Iveta Selingerova, Zdenek Rehak, Vaclav Jedlicka, Marek Slavik, Pavel Fabian, Ivo Novotny, Milada Zemanova, Hana Studentova, Peter Grell, Lenka Zdrazilova Dubska, Regina Demlova, Tomas Harustiak, Renata Hejnova, Igor Kiss, Rostislav Vyzula
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Perioperative chemotherapy is a recommended treatment approach for localised oesophago-gastric junction adenocarcinoma, but not all patients respond to neoadjuvant chemotherapy. Early identification of non-responders and treatment adaptat
Externí odkaz:
https://doaj.org/article/fdb8af992495421d81803942b0afe118
Autor:
Marek Slavik, Petr Burkon, Iveta Selingerova, Pavel Krupa, Tomas Kazda, Jaroslava Stankova, Tomas Nikl, Renata Hejnova, Zdenek Rehak, Pavel Osmera, Tomas Prochazka, Eva Dvorakova, Petr Pospisil, Peter Grell, Pavel Slampa, Radka Obermannova
Publikováno v:
Medicina, Vol 57, Iss 12, p 1334 (2021)
Background and Objectives: The treatment of gastroesophageal junction (GEJ) adenocarcinoma consists of either perioperative chemotherapy or preoperative chemoradiotherapy. Radiotherapy (RT) in the neoadjuvant setting is associated with a higher proba
Externí odkaz:
https://doaj.org/article/79db9a736a0a47dbae7bbef26babd408
Publikováno v:
Cancers, Vol 13, Iss 5428, p 5428 (2021)
Cancers
Cancers
Simple Summary Clinical trials in pediatric oncology and personalized medicine are challenging due to the rarity of the disease, the low prevalence, and the ever-improving treatment outcomes. Many of the methods designed for small numbers and approac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c5d65a3560e96bd94458a43cfa9c7e
https://www.mdpi.com/2072-6694/13/21/5428
https://www.mdpi.com/2072-6694/13/21/5428
Autor:
Lenka Zdrazilova-Dubska, Peter Grell, Rostislav Vyzula, Lubos Petruzelka, Hana Študentová, Renata Hejnova, Ondrej Slaby, Radka Obermannova, Regina Demlová
Publikováno v:
Journal of Clinical Oncology. 36:TPS202-TPS202
TPS202 Background: The standard treatment approach in locally advanced oesophago-gastric cancer (OGC) contains surgery with perioperative chemotherapy (CXT). Nonetheless according to sequential 18FDG-PET-CT only 40–50% of the patients respond to CT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ba36738a8e4f8572f9594cdb0cbda79
https://doi.org/10.1200/jco.2018.36.4_suppl.tps202
https://doi.org/10.1200/jco.2018.36.4_suppl.tps202